InterveXion Enrolls First Patient in OUTLAST, a Phase 2 Study of IXT-m200 in Methamphetamine Use Disorder
- First clinical trial of an anti-METH antibody in patients seeking treatment for methamphetamine use disorder LITTLE ROCK, ARKANSAS, USA, July 5, 2022 /EINPresswire.com/ -- InterveXion Therapeutics, a clinical-stage biopharmaceutical company, today …